Back to search
FDAFDA · Food and drugs·Recall number D-0390-2025

Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01

Published May 7, 2025 · Recall initiated: April 21, 2025

Summary

FDA records drug Class II recall D-0390-2025, published May 7, 2025 and initiated April 21, 2025. Recalling firm: Eugia US LLC; Status: Ongoing; Lot: Lot# : 3TF24001, Exp 3/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

What to do

Voluntary: Firm initiated · Letter

Get an email if TIROFIBAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TIROFIBAN
Manufacturer
Eugia US LLC
Distributor
USA nationwide.
UPC
0355150430017
Lot
Lot# : 3TF24001, Exp 3/31/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01 recalled?

Yes. FDA published recall D-0390-2025 on May 7, 2025. Reported hazard: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TIROFIBAN. UPC: 0355150430017.